New diabetes drug HM15275 enters Mid-Stage trial
Disease control
Not yet recruiting
This study tests a new medicine called HM15275 in 180 adults with type 2 diabetes. Participants must be on diet and exercise or a stable dose of metformin. The goal is to see if the drug safely lowers blood sugar levels over 36 weeks compared to a placebo.
Phase: PHASE2 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated May 01, 2026 15:58 UTC